Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ling Li, Jingkui Yu, Shuhong Jiao, Wei Wang, Fen Zhang & Shiqing Sun. (2018) Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells. OncoTargets and Therapy 11, pages 8543-8553.
Read now
Read now
Zijun Huo, Shuang Yu, Shubin Hong, Xiaopei Cao, Lingling Xiu, Zhihong Liao, Yanbing Li & Haipeng Xiao. (2016) A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients. OncoTargets and Therapy 9, pages 3621-3631.
Read now
Read now
Shuang Zhang, Min Yu & Yuquan Wei. (2014) Do anti-angiogenic cancer therapies increase risk of significant weight loss?. Expert Opinion on Drug Safety 13:4, pages 473-482.
Read now
Read now
Articles from other publishers (24)
Yiying Wang, Xiaoyu Wang, Kexin Su & Yifu Yang. (2023) Traditional Chinese Medicine Targeting Sarcoma Virus Oncogene-related
Diseases. Current Cancer Drug Targets 23:10, pages 751-763.
Crossref
Crossref
Abdalla R. Mohamed & Ahmed M. El Kerdawy. (2022) A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry. Chemistry & Biodiversity 19:10.
Crossref
Crossref
Kaushik Neogi, Prashant R. Murumkar, Priyanshu Sharma, Poonam Yadav, Mallika Tewari, Devarajan Karunagaran, Prasanta Kumar Nayak & Mange Ram Yadav. (2022) Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway. Translational Oncology 19, pages 101395.
Crossref
Crossref
Ming Guo, Yankun Duan, Shuyan Dai, Jun Li, Xiaojuan Chen, Lingzhi Qu, Zhuchu Chen, Hudie Wei, Longying Jiang & Yongheng Chen. (2022) Structural study of ponatinib in inhibiting SRC kinase. Biochemical and Biophysical Research Communications 598, pages 15-19.
Crossref
Crossref
Sushanta Bhattacharya, Vivek Asati, Amena Ali, Abuzer Ali & G.D. Gupta. (2022) In-silico studies for the development of novel RET inhibitors for cancer treatment. Journal of Molecular Structure 1251, pages 132040.
Crossref
Crossref
Jillian Hattaway Luttman, Ashley Colemon, Benjamin Mayro & Ann Marie Pendergast. (2021) Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade. Cell Communication and Signaling 19:1.
Crossref
Crossref
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith & Brendan Frett. (2021) Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of Medicinal Chemistry 64:16, pages 11747-11773.
Crossref
Crossref
Mohd. Imran, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Dhanalekshmi Unnikrishnan Meenakshi, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani, Yahya Mohzari, Ahmed Alrashed, Mohammed AlMotairi, Eman H. Alkhaldi, Abeer K. Alorabi, Ahmed Subeh Alshrari, Mohammad Tauseef, Abida, Saleh I. Alaqel, Ozair Alam & Md. Afroz Bakht. (2021) Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals 14:8, pages 710.
Crossref
Crossref
Jeffrey S. Ross, Ethan S. Sokol, Holger Moch, Linda Mileshkin, Giulia Baciarello, Ferran Losa, Andreas Beringer, Marlene Thomas, Julia A. Elvin, Nhu Ngo, Dexter X. Jin & Alwin Krämer. (2021) Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. The Oncologist 26:3, pages e394-e402.
Crossref
Crossref
Ayse Caner, Elif Asik & Bulent Ozpolat. 2021. Tumor Microenvironment. Tumor Microenvironment
57
71
.
Julia López de Andrés, Carmen Griñán-Lisón, Gema Jiménez & Juan Antonio Marchal. (2020) Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Naga Rajiv Lakkaniga, Naresh Gunaganti, Lingtian Zhang, Binyam Belachew, Brendan Frett, Yuet-Kin Leung & Hong-yu Li. (2020) Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry 206, pages 112691.
Crossref
Crossref
Vivek Subbiah & Gilbert J. Cote. (2020) Advances in Targeting RET-Dependent Cancers. Cancer Discovery 10:4, pages 498-505.
Crossref
Crossref
Rania S.M. Ismail, Sahar M. Abou-Seri, Wagdy M. Eldehna, Nasser S.M. Ismail, Sara M. Elgazwi, Hazem A. Ghabbour, Mahmoud Salama Ahmed, Fathi T. Halaweish & Dalal A. Abou El Ella. (2018) Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. European Journal of Medicinal Chemistry 155, pages 782-796.
Crossref
Crossref
Qin Xie, Hui Chen, Jing Ai, Ying-lei Gao, Mei-yu Geng, Jian Ding & Yi Chen. (2017) Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Acta Pharmacologica Sinica 38:11, pages 1533-1542.
Crossref
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Crossref
Sandra Lassalle, Joséphine Zangari, Alexandra Popa, Marius Ilie, Véronique Hofman, Elodie Long, Martine Patey, Frédérique Tissier, Geneviève Belléannée, Hélène Trouette, Bogdan Catargi, Isabelle Peyrottes, Jean-Louis Sadoul, Olivier Bordone, Christelle Bonnetaud, Catherine Butori, Alexandre Bozec, Nicolas Guevara, José Santini, Imène Sarah Hénaoui, Géraldine Lemaire, Olivier Blanck, Philippe Vielh, Pascal Barbry, Bernard Mari, Patrick Brest & Paul Hofman. (2016)
MicroRNA-375/SEC23A as biomarkers of the
in vitro
efficacy of vandetanib
. Oncotarget 7:21, pages 30461-30478.
Crossref
Crossref
Tuo Li, Jianguo Sheng, Weiqin Li, Xin Zhang, Hongyu Yu, Xueyun Chen, Jianquan Zhang, Quancai Cai, Yongquan Shi & Zhimin Liu. (2015) A new computational model for human thyroid cancer enhances the preoperative diagnostic efficacy. Oncotarget 6:29, pages 28463-28477.
Crossref
Crossref
D. Hartl. (2015) Tumori del corpo della tiroide. EMC - Otorinolaringoiatria 14:3, pages 1-12.
Crossref
Crossref
D. Hartl. (2015) Tumores de la gl?ndula tiroidea. EMC - Otorrinolaringolog?a 44:3, pages 1-14.
Crossref
Crossref
Huan‐gao Zhu, Jun‐yu Zhao, Rui Zhang, Lin Liao & Jian‐jun Dong. (2015) New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism. Thoracic Cancer 6:4, pages 539-543.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2015) Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research 94, pages 9-25.
Crossref
Crossref
Jeffrey S. Ross, Kai Wang, Laurie Gay, Geoff A. Otto, Emily White, Kiel Iwanik, Gary Palmer, Roman Yelensky, Doron M. Lipson, Juliann Chmielecki, Rachel L. Erlich, Andrew N. Rankin, Siraj M. Ali, Julia A. Elvin, Deborah Morosini, Vincent A. Miller & Philip J. Stephens. (2015) Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site. JAMA Oncology 1:1, pages 40.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2014) ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacological Research 87, pages 42-59.
Crossref
Crossref